Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNEC) is an abnormal proliferation of pulmonary neuroendocrine cells that occur without underlying etiology. Here, we report a unique case of 55-year-old female with unusual presentation of DIPNECH and thymoma and on the background history of Crohn's disease that might point toward an autoimmune phenomenon. To the best of our knowledge, there were no previous reports of DIPNECH with either thymoma or Crohn's disease. DIPNECH has premalignant potential and reported in association with carcinoid and non-small cell lung cancer; however, its autoimmune association never reported. The presence of multiple lung nodules along with evidence of small airway disease should alert the physician to include DIPNECH as part of the differential diagnosis given its malignant potential. The prognosis is variable and depends on the presence or absence of underlying malignancy as well as the severity of airflow obstruction.
P ulmonary neuroendocrine cells (PNECs) are normal specialized epithelial cells lining the tracheobronchial tree and can present solitary or in the cluster. PNECS are normally few as human grow in comparison to the fatal lung. An abnormally high rate of PNECS proliferation can occur with different respiratory disorders that are associated with hypoxia. [1] When the proliferation occurs without obvious reasons, the term Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNEC) is applied. DIPNECH is considered premalignant lesion by the last update from the World Health Organization (WHO). [2] Here, we report a patient with DIPNECH that coincides with a diagnosis of thymoma and on background history of Crohn's disease. We believe that this is the first report of such association.
Case Report
A 55-year-old female presented to our outpatient clinic with prolong history of productive cough associated with wheezes for the last 5 years associated with recurrent chest infection requiring outpatient treatment with oral antibiotics along with a short course of oral steroid. She is a nonsmoker or passive smoker. There is no family history of malignancy. Her background history is significant for Crohn's disease since 2014 treated with azathioprine. On physical examination, auscultation was significant for bibasilar fine inspiratory crackles. There were no wheezes. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. As thymoma was the WHO Type B2 and the margin of the resection was involved by the thymoma, she underwent radiotherapy of 22 sessions. She remains stable and on regular follow-up.
Discussion
Our case demonstrates unique presentation of DIPNECH with a concomitant diagnosis of thymoma and on the background of Crohn's disease. Up to our knowledge, there are no previous reports of DIPNECH with either thymoma or Crohn's disease.
The diagnosis of DIPNECH is made in appropriate clinical scenario of obstructive symptoms along with PFT findings of obstructive ventilator defect and/or air trapping in conjunction with CT findings of lung nodules with or without signs of small airway disease. Restrictive and normal PFT finding has been reported as well. [3] In some cases, the patient can be asymptomatic, and diagnosis is made through incidental finding of lung nodule. [4] Lung biopsy is required to confirm the diagnosis and to rule out carcinoid tumor in the presence of lung nodule. The gold standard test is surgical lung biopsy as it provides the ideal sufficient sample given the nature of its patchy bronchiolar involvement that can be missed by conventional transbronchial biopsy. [5] Up to date, there is no consensus in treating DEIPNECH. The management largely depends on presence and severity of symptoms as well as the severity of airflow obstruction on PFT. Therapeutic options include surgical resection, steroid, somatostatin analog, and cytotoxic therapy. Watch and see approach can be considered in asymptomatic patient with regular clinical follow-up. [5] Prognosis is variable and depends on the degree of constrictive bronchiolitis and its associated airflow obstruction as well as its presence of associated malignancy. Davis SJ and coworkers estimate 5-year survival rate of 83%. Progressive airflow obstruction secondary to obliterative bronchiolitis can be stabilized with steroid therapy, but in other cases would require lung transplantation. DIPNECH is considered premalignant lesion according to the latest WHO update and serial radiologic monitoring in the presence of lung nodule and low threshold for surgical biopsy of >0.5 cm or increasing size nodule due it is carcinoid potential. [5] DEPNICH has been reported in the patient with a current or previous history of intrathoracic or extrathoracic malignancies. Thymoma is associated with other autoimmune disorders, such as systemic lupus erythematosus and Sjogren's syndrome. [6] Up to our knowledge, this is the first case reported the presence of DEPNICH in association with Crohn's disease and with thymoma. This might point toward a possible underlying autoimmune stimulus for PNECs to proliferate, however, its autoimmune association not demonstrated.
In summary, here, we report a unique case of DIPNECH in a patient with Crohn's disease and thymoma. The presence of multiple lung nodules along with evidence of small airway disease should rise the suspicion of DIPNECH as part of the differential diagnosis given its malignant potential.
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